speb/financial-data huggingface dataset:
Financial scorecard for GSN.AX (Basic Materials — Other Precious Metals & Mining, Australia)
Report date: 2025-06-30 (annual)
Stock price: 0.01388888888888889
Market cap: 25727114 (USD: 16815107.189542484)
Debt to equity: 0.003
Current ratio: 3.14
Buffett classification: The Gruesome
Rule of 40 score: 0
Piotroski F-score: 1 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Total shareholder yield (%): 0 (Minimal or Negative)
Momentum (%): 1m 0.6944444444444402, 3m -35.18518518518518, 6m -59.44444444444446, 12m -30.09259259259259, composite -41.734780757769265 (Strong Downtrend)
Lynch category: Cyclical (confidence: High)
Screener: long score 2, short score 2, recommendation: Neutral
Revenue deceleration: no
Beneish M-score: -2.48 (Likely Safe)
ROE archetype: Standard Business
Treasury beta 1y: 0.0009844949807030988 (R-squared: 6.5860882216114696e-06)
Insider 90-day net shares: 2524148 (net value USD: 33571.00)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B , ROIC , revenue growth 1y , 6m momentum 69.62750716332378
Sector percentiles: P/E , 6m momentum 77.79011660188783
Industry median P/E: 8.740359897172237; industry median ROIC: -12.638421644657798
Sector median P/E: 1.5790983881237224; sector median ROIC: -1.992018401665734
WACC: 0.0942
Base cash flow: 0
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for HC.V (Consumer Cyclical — Auto Parts, Canada)
Report date: 2025-12-31 (quarterly)
Stock price: 0.06382978723404255
Market cap: 13163714 (USD: 9608550.364963504)
P/B ratio: 3.468525975797697
Debt to equity: 0
Current ratio: 2.01
Return on net tangible assets (%): -12.615357829341198
Buffett classification: The Gruesome
Rule of 40 score: -70.8344607924288
Altman Z-score: -2.1804382906927513 (Distress Zone)
Piotroski F-score: 4 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 0
Total shareholder yield (%): 0 (Minimal or Negative)
Momentum (%): 1m -9.361702127659585, 3m 9.308510638297868, 6m -2.1276595744680904, 12m -13.19148936170214, composite 0.9851663170512408 (Moderate Downtrend)
Lynch category: Cyclical (confidence: High)
Screener: long score 2, short score 10, recommendation: Strong Short (Melting Ice Cube)
Revenue growth 1y (%): -45.89261610755236
Revenue deceleration: no
Accrual ratio: 0.10007913253202626
FCF conversion rate: 2.3901488906339012
Beneish M-score: -2.2556888424495334 (Likely Safe)
ROE (%): -20.98970603486602
Net margin (%): -17.61482030232326
Asset turnover: 0.4086993977740625
Equity multiplier (leverage): 2.9155744879946086
ROE archetype: Low Return
Treasury beta 1y: 0.00039796023580027817 (R-squared: 2.3964878693009836e-06)
Insider 90-day net shares: 181250 (net value USD: 10212.00)
Incremental ROIC 3y (%): -381.1889828670906 (pretax: -482.5176998317602)
Capital allocation category: Value Destroyer
Industry percentiles: P/E , P/B 67.21763085399449, ROIC , revenue growth 1y 66.11570247933885, 6m momentum 43.52617079889807
Sector percentiles: P/E , 6m momentum 37.30876216968011
Industry median P/E: 0.2842479295922772; industry median ROIC: 7.591641841963527
Sector median P/E: 0.5734625271900335; sector median ROIC: 5.974200780604355
WACC: 0.15
Base cash flow: -2869709.090909091
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for HCAT (Healthcare — Health Information Services, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 2.08
Market cap: 153699552 (USD: 153699552)
P/B ratio: 0.6793253856455174
Debt to equity: 1.2348000000000001
Current ratio: 1.69
Interest coverage ratio: -1.5105440742302825
Buffett classification: The Gruesome
Analyst consensus upside (%): 77.16535433070865
Rule of 40 score: 7.81429289439378
Altman Z-score: -4.343692177088987 (Distress Zone)
Piotroski F-score: 4 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 0.4294091891692697
Total shareholder yield (%): 0.4294091891692697 (Low Return)
Momentum (%): 1m 20.93023255813954, 3m 50.724637681159436, 6m -7.555555555555553, 12m -45.97402597402597, composite -4.051864399690477 (Strong Downtrend)
Lynch category: Turnaround (confidence: High)
Screener: long score 2, short score 11, recommendation: Short
Revenue growth 1y (%): -10.901237832596678
Revenue deceleration: no
Accrual ratio: -0.27117599156141203
FCF conversion rate: -0.1172338010916362
Beneish M-score: -3.0276421941139984 (Likely Safe)
ROE (%): -57.83733802174904
Net margin (%): -156.91390129458986
Asset turnover: 0.15468412681929725
Equity multiplier (leverage): 2.3828742592954355
ROE archetype: Low Return
Treasury beta 1y: 0.03643242272529202 (R-squared: 0.030163532287470707)
Insider 90-day net shares: 0 (net value USD: 0.00)
ROIC (%): -10.51018718524928 (pretax: -13.30403441170795)
Incremental ROIC 3y (%): 651.5959124830393 (pretax: 824.8049525101765)
Capital allocation category: Turnaround Compounder
Industry percentiles: P/E , P/B 9.473684210526317, ROIC 40, revenue growth 1y 38.421052631578945, 6m momentum 30.526315789473685
Sector percentiles: P/E , 6m momentum 37.750716332378225
Industry median P/E: 8.33027298322928; industry median ROIC: 0.6291287571896624
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.1227372527366363
Base cash flow: -128398000
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for HCH.V (Basic Materials — Copper, Australia)
Report date: 2025-06-30 (annual)
Stock price: 1.049645390070922
Market cap: 300237536 (USD: 196233683.6601307)
P/B ratio: 0.4632537670959545
Debt to equity: 0.0014000000000000002
Current ratio: 2.41
Interest coverage ratio: -217.5092654650847
Return on net tangible assets (%): -6.827968566724136
Buffett classification: The Gruesome
Analyst consensus upside (%): 926.1020408163267
Rule of 40 score: 0
Piotroski F-score: 0 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 0.05009201780819306
Total shareholder yield (%): 0.05009201780819306 (Low Return)
Momentum (%): 1m -19.865782048348972, 3m -2.175905823322232, 6m -11.134316668842184, 12m 150.44170710464104, composite 66.40585862566599 (Strong Uptrend)
Lynch category: Cyclical (confidence: High)
Screener: long score 2, short score 2, recommendation: Neutral
Revenue deceleration: no
Accrual ratio: 0.07921078334406605
FCF conversion rate: 2.780517559207606
Beneish M-score: -2.7866815318695 (Likely Safe)
ROE (%): -4.527354401030422
Equity multiplier (leverage): 1.0176687652205096
ROE archetype: Low Return
Treasury beta 1y: 0.02154988811330171 (R-squared: 0.013608816705508257)
Insider 90-day net shares: 0 (net value USD: 0.00)
ROIC (%): -4.038973023629109 (pretax: -5.112624080543175)
Incremental ROIC 3y (%): -16.614232292947495 (pretax: -21.03067378854113)
Capital allocation category: Value Destroyer
Industry percentiles: P/E , P/B 9.090909090909092, ROIC 38.38383838383838, revenue growth 1y , 6m momentum 30.303030303030305
Sector percentiles: P/E , 6m momentum 35.95224875069406
Industry median P/E: 8.111238786291718; industry median ROIC: 1.4751649297193823
Sector median P/E: 1.5790983881237224; sector median ROIC: -1.992018401665734
WACC: 0.11509088917204069
Base cash flow: -9719133.333333334
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for HIDE.V (Technology — Software - Application, Canada)
Report date: 2026-01-31 (quarterly)
Stock price: 0.12056737588652484
Market cap: 6108100 (USD: 4524518.518518519)
P/B ratio: 25.499368435314466
Debt to equity: 0
Current ratio: 8.97
Return on net tangible assets (%): -53.49944514697154
Buffett classification: The Gruesome
Rule of 40 score: 0
Altman Z-score: 78.36444341401948 (Safe Zone)
Piotroski F-score: 3 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Total shareholder yield (%): 0 (Minimal or Negative)
Momentum (%): 1m -69.4275582573455, 3m -72.00384661617983, 6m -38.376674546887315, 12m -3.5460992907801248, composite 35.03747886113725 (Strong Uptrend)
Lynch category: Speculative (confidence: Low)
Screener: long score 4, short score 12, recommendation: Short
Revenue deceleration: no
Accrual ratio: 0.03412885079672648
FCF conversion rate: 1.0881783643440732
Beneish M-score: -2.578475363356587 (Likely Safe)
ROE (%): -41.3835433754607
Asset turnover: 0
Equity multiplier (leverage): 1.0692223970108423
ROE archetype: Low Return
Treasury beta 1y: -0.021217111696100004 (R-squared: 0.0025438451067418253)
Insider 90-day net shares: -690000 (net value USD: -71070.00)
ROIC (%): -244.7249809014513 (pretax: -309.77845683728015)
Incremental ROIC 3y (%): -176.72162806889776 (pretax: -223.69826337835156)
Capital allocation category: Value Destroyer
Industry percentiles: P/E , P/B 73.18059299191376, ROIC 76.81940700808624, revenue growth 1y , 6m momentum 74.93261455525607
Sector percentiles: P/E , 6m momentum 71.5382048715382
Industry median P/E: 2.1394954536591486; industry median ROIC: 6.21806735836372
Sector median P/E: 1.5433673469387754; sector median ROIC: 6.677876317240262
WACC: 0.05790000000000001
Base cash flow: -246809.42028985507
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for HONASA.NS (Consumer Defensive — Household & Personal Products, India)
Report date: 2026-03-31 (annual)
Stock price: 4.6304706853839805
Market cap: 146254462976 (USD: 1549962515.6422212)
P/E ratio: 0.5158624459057904
P/B ratio: 6.8566560738665165
Debt to equity: 0.0959
Current ratio: 1.69
Interest coverage ratio: 14.595372202770589
Return on net tangible assets (%): 22.43754598283559
Buffett classification: The Great
Analyst consensus upside (%): 14774.660385582563
Rule of 40 score: 9.299492871411234
Altman Z-score: 14.562148432037496 (Safe Zone)
Piotroski F-score: 3 (Weak)
Magic formula: return on capital % 12.617300980207746, earnings yield % 0.004941383946769791, rank 1842
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 0.10336886008023632
Total shareholder yield (%): 0.10336886008023632 (Low Return)
Momentum (%): 1m 5.957014024485477, 3m 24.91718394768134, 6m 55.984509180926146, 12m 45.34883459297945, composite 39.35962146369616 (Strong Uptrend)
Lynch category: Fast Grower (confidence: Medium)
Screener: long score 10, short score 0, recommendation: Strong Long (L/S Compounder)
Revenue growth 1y (%): 11.639772310417928
Net income growth 1y (%): 152.00169923150875
Revenue deceleration: no
Accrual ratio: 0.03259430472134616
FCF conversion rate: 0.6688945501773316
Beneish M-score: -1.8992728885552639 (Likely Safe)
ROE (%): 4.918220890008301
Net margin (%): 10.567598663184615
Asset turnover: 0.3140195384072786
Equity multiplier (leverage): 1.482091607335613
ROE archetype: Low Return
P/E z-score: 3.6967646875853952
FCF z-score: 3.6967646875853943
Treasury beta 1y: -7.175442477375616e-05 (R-squared: 9.348148609582637e-07)
Insider 90-day net shares: 0 (net value USD: 0.00)
ROIC (%): 14.516954463402815 (pretax: 18.655580893970402)
Incremental ROIC 3y (%): 26.576641786795136 (pretax: 34.14672690237231)
Capital allocation category: Standard Allocator
Industry percentiles: P/E 27.071823204419886, P/B 59.66850828729282, ROIC 32.59668508287293, revenue growth 1y 9.94475138121547, 6m momentum 1.6574585635359116
Sector percentiles: P/E 27.8783490224475, 6m momentum 1.66545981173063
Industry median P/E: 1.0386203196660713; industry median ROIC: 10.090126010498068
Sector median P/E: 1.0302878025850322; sector median ROIC: 7.163828537874342
WACC: 0.08044951805954441
Base cash flow: 25177299.703264095
DCF price per share: base 0.02139799043109143, conservative 0.013173766341490666, aggressive 0.03549765911772762
Financial scorecard for IAU.TO (Basic Materials — Gold, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 1.3546099290780143
Market cap: 1646517632 (USD: 1646517632)
P/B ratio: 4.378048672496081
Debt to equity: 1.4782
Current ratio: 9.46
Interest coverage ratio: -3.75848406546081
Return on net tangible assets (%): -29.945867458915476
Buffett classification: The Gruesome
Analyst consensus upside (%): 185.2464454976303
Rule of 40 score: 32.59066414041955
Altman Z-score: 0.9437305619895539 (Distress Zone)
Piotroski F-score: 6 (Neutral)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): -15.980150767070558
Total shareholder yield (%): -15.980150767070558 (Minimal or Negative)
Momentum (%): 1m -3.339391995438188, 3m -13.68299521688931, 6m -25.523438162244638, 12m 109.34880722114768, composite 25.79162421293061 (Strong Uptrend)
Lynch category: Cyclical (confidence: High)
Screener: long score 1, short score 9, recommendation: Short
Revenue growth 1y (%): 272.9356492027335
Revenue deceleration: no
Accrual ratio: -0.023051918687854785
FCF conversion rate: 0.7243673744608847
Beneish M-score: -0.6935467392585358 (Strong Manipulation Signal)
ROE (%): -24.347150010299394
Net margin (%): -150.03054017942355
Asset turnover: 0.05574382737395394
Equity multiplier (leverage): 2.911197533101326
ROE archetype: Low Return
Treasury beta 1y: -9.366972636255249e-05 (R-squared: 4.0617916030269657e-07)
Insider 90-day net shares: 1106230 (net value USD: 1553026.00)
ROIC (%): -16.91763666121113 (pretax: -21.414729950900163)
Incremental ROIC 3y (%): -50.0640658303924 (pretax: -63.372235228344806)
Capital allocation category: Value Destroyer
Industry percentiles: P/E , P/B 43.05949008498583, ROIC 38.38526912181303, revenue growth 1y 0.708215297450425, 6m momentum 35.8356940509915
Sector percentiles: P/E , 6m momentum 50.277623542476405
Industry median P/E: 8.322060300477567; industry median ROIC: -7.9824265928961236
Sector median P/E: 1.5790983881237224; sector median ROIC: -1.992018401665734
WACC: 0.15
Base cash flow: -205221000
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for IFA.TO (Consumer Cyclical — Apparel Manufacturing, Canada)
Report date: 2026-03-31 (quarterly)
Stock price: 3.673758865248227
Market cap: 189154784 (USD: 136082578.4172662)
P/E ratio: 18.225419664268586
P/B ratio: 4.513942574196391
Debt to equity: 0.5447
Current ratio: 1.8
Interest coverage ratio: 42.965972696245736
Return on net tangible assets (%): 15.340008154020682
Buffett classification: The Great
Analyst consensus upside (%): 294.5953947368421
Rule of 40 score: 129.87012534306484
Altman Z-score: 6.049812992220133 (Safe Zone)
Piotroski F-score: 6 (Neutral)
Magic formula: return on capital % 21.201943908285013, earnings yield % 2.1488934470516092, rank 162
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): -1.238070872514403
Total shareholder yield (%): -1.238070872514403 (Minimal or Negative)
Momentum (%): 1m 6.9003604232066005, 3m 13.869901479413382, 6m 181.65484633569736, 12m 431.5225592274031, composite 197.57927114764007 (Strong Uptrend)
Lynch category: Slow Grower (confidence: Medium)
Screener: long score 7, short score 2, recommendation: Neutral
Revenue growth 1y (%): 299.6099036279053
Net income growth 1y (%): 4215.022664090799
Revenue deceleration: no
Accrual ratio: 0.17956260542448146
FCF conversion rate: -1.2670716567831397
Beneish M-score: -0.43873172512290737 (Strong Manipulation Signal)
ROE (%): 16.27562381132062
Net margin (%): 13.490365216936013
Asset turnover: 0.5871200933117234
Equity multiplier (leverage): 2.054882493595134
ROE archetype: Balanced Compounder
Treasury beta 1y: -0.00023888305711781407 (R-squared: 1.4665998282168113e-06)
Insider 90-day net shares: -2052000 (net value USD: -5809211.00)
ROIC (%): 1.2175946387630112 (pretax: 1.8732225211738631)
Incremental ROIC 3y (%): -17.819578876089405 (pretax: -22.070848907446337)
Capital allocation category: Value Destroyer
Industry percentiles: P/E 52.86624203821656, P/B 68.15286624203821, ROIC 57.961783439490446, revenue growth 1y 0, 6m momentum 1.2738853503184715
Sector percentiles: P/E 52.57301808066759, 6m momentum 0.7301808066759388
Industry median P/E: 0.8420334714862808; industry median ROIC: 4.712308174264459
Sector median P/E: 0.5734625271900335; sector median ROIC: 5.974200780604355
WACC: 0.05
Base cash flow: -153648.90510948905
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for IMI.V (Industrials — Engineering & Construction, Canada)
Report date: 2026-02-28 (quarterly)
Stock price: 0.06382978723404255
Market cap: 16490582 (USD: 12036921.16788321)
P/E ratio: 4.744525547445255
P/B ratio: 12.206031752041781
Debt to equity: 13.4296
Current ratio: 0.87
Interest coverage ratio: -0.8918416011388429
Buffett classification: The Gruesome
Rule of 40 score: -21.29111685448947
Altman Z-score: 0.9208475348676659 (Distress Zone)
Piotroski F-score: 0 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Total shareholder yield (%): 0 (Minimal or Negative)
Momentum (%): 1m -9.361702127659585, 3m -2.836879432624105, 6m -26.59574468085107, 12m -3.5460992907801305, composite -7.672116227705071 (Flat)
Lynch category: Cyclical (confidence: High)
Screener: long score 0, short score 11, recommendation: Strong Short (Melting Ice Cube)
Revenue deceleration: no
Accrual ratio: 0.020878435533241764
FCF conversion rate: 1.8960917722616397
Beneish M-score: -2.3861692833039383 (Likely Safe)
ROE (%): -38.994451965990265
Net margin (%): -11.228948496039111
Asset turnover: 0.2074943967291875
Equity multiplier (leverage): 16.736219299066473
ROE archetype: Low Return
P/E z-score: 2.9427944124599845
FCF z-score: 1.8311226619472574
Treasury beta 1y: 0.027678677073295885 (R-squared: 0.01117230834738132)
Insider 90-day net shares: 0 (net value USD: 0.00)
ROIC (%): 10.536428451088238 (pretax: 16.209889924751135)
Capital allocation category: Standard Allocator
Industry percentiles: P/E 52.67702936096719, P/B 79.62003454231433, ROIC 35.233160621761655, revenue growth 1y , 6m momentum 81.00172711571675
Sector percentiles: P/E 44.31643625192012, 6m momentum 74.42396313364056
Industry median P/E: 0.3073205413493449; industry median ROIC: 8.170542376375224
Sector median P/E: 0.48479532163742683; sector median ROIC: 7.0952301251284755
WACC: 0.05
Base cash flow: 677771.2230215827
DCF price per share: base 0.273851034749856, conservative 0.10234058248210116, aggressive 0.6280019412125423
Financial scorecard for INFU (Healthcare — Medical Devices, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 9.12
Market cap: 184057136 (USD: 184057136)
P/E ratio: 24.945945945945947
P/B ratio: 3.170728330524775
Debt to equity: 0.4103
Current ratio: 2.14
Interest coverage ratio: 6.235294117647059
Return on net tangible assets (%): 6.2211933943740565
Buffett classification: The Gruesome
Analyst consensus upside (%): 61.21343445287108
Rule of 40 score: -13.261739386009172
Altman Z-score: 2.5401480513676544 (Grey Zone)
Piotroski F-score: 5 (Neutral)
Magic formula: return on capital % 2.613584062068512, earnings yield % 0.7716381308738647, rank 2000
Dividend yield (%): 0
Buyback yield (%): 0.5291835031052531
Debt paydown yield (%): 0.1553865317126308
Total shareholder yield (%): 0.6845700348178839 (Low Return)
Momentum (%): 1m -0.3278688524590288, 3m -11.798839458413934, 6m 7.547169811320741, 12m 54.31472081218273, composite 16.85688845942917 (Strong Uptrend)
Lynch category: Slow Grower (confidence: Low)
Screener: long score 3, short score 3, recommendation: Neutral
Revenue growth 1y (%): -2.972692706533009
Revenue deceleration: no
Accrual ratio: 0.018914048499877018
FCF conversion rate: -0.8525073746312685
Beneish M-score: -2.444073249856388 (Likely Safe)
ROE (%): 1.752315313374973
Net margin (%): 3.0192376202351263
Asset turnover: 0.3381639117143617
Equity multiplier (leverage): 1.7162782683609734
ROE archetype: Low Return
P/E z-score: 4.427450227512689
FCF z-score: 4.4274502275126855
Treasury beta 1y: 0.00446457658670206 (R-squared: 0.0012665407358547459)
Insider 90-day net shares: 17064 (net value USD: 150375.00)
ROIC (%): 10.03730956575811 (pretax: 15.44201471655094)
Capital allocation category: Capital-Light Grower
Industry percentiles: P/E 20.178041543026705, P/B 40.94955489614243, ROIC 13.649851632047477, revenue growth 1y 46.88427299703264, 6m momentum 13.056379821958458
Sector percentiles: P/E 26.325214899713465, 6m momentum 21.63323782234957
Industry median P/E: 21.626420273203117; industry median ROIC: -5.9391058628332924
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.11404222703006124
Base cash flow: 14543000
DCF price per share: base 12.348740797735417, conservative 8.381820234836614, aggressive 18.218494099497914
Financial scorecard for INGN (Healthcare — Medical Devices, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 6.15
Market cap: 166508272 (USD: 166508272)
P/B ratio: 0.9147896125878866
Debt to equity: 0.0926
Current ratio: 3.1
Return on net tangible assets (%): -2.9272609450014984
Buffett classification: The Gruesome
Analyst consensus upside (%): 105.01618122977348
Rule of 40 score: -6.917646604940043
Altman Z-score: 0.8015045749151829 (Distress Zone)
Piotroski F-score: 4 (Weak)
Dividend yield (%): 0
Buyback yield (%): 1.125469610302604
Debt paydown yield (%): 0.3249087829101968
Total shareholder yield (%): 1.450378393212801 (Low Return)
Momentum (%): 1m -9.023668639053247, 3m -12.765957446808503, 6m 1.9900497512437827, 12m -9.558823529411757, composite -3.788047663227456 (Moderate Downtrend)
Lynch category: Turnaround (confidence: High)
Screener: long score 2, short score 10, recommendation: Strong Short (Melting Ice Cube)
Revenue growth 1y (%): 3.4382596013612154
Revenue deceleration: no
Accrual ratio: -0.002935586458666566
FCF conversion rate: 0.8969245555021624
Beneish M-score: -2.480451643070449 (Likely Safe)
ROE (%): -4.43784537382343
Net margin (%): -9.78039925272298
Asset turnover: 0.29119443812430396
Equity multiplier (leverage): 1.5582333920674314
ROE archetype: Low Return
Treasury beta 1y: -0.00499276899160148 (R-squared: 0.00227105647017969)
Insider 90-day net shares: -21708 (net value USD: -142459.00)
ROIC (%): -26.47678908243648 (pretax: -33.514922889160104)
Capital allocation category: Capital-Light Grower
Industry percentiles: P/E , P/B 13.649851632047477, ROIC 42.72997032640949, revenue growth 1y 36.795252225519285, 6m momentum 18.397626112759642
Sector percentiles: P/E , 6m momentum 26.07449856733524
Industry median P/E: 21.626420273203117; industry median ROIC: -5.9391058628332924
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.1272077888180773
Base cash flow: -12471000
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for INMB (Healthcare — Biotechnology, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 1.62
Market cap: 43068120 (USD: 43068120)
P/B ratio: 1.530847000611496
Debt to equity: 0.077
Current ratio: 4.24
Return on net tangible assets (%): -27.288014675907053
Buffett classification: The Gruesome
Analyst consensus upside (%): 519.4690265486727
Rule of 40 score: 0
Altman Z-score: -7.3890220559589865 (Distress Zone)
Piotroski F-score: 3 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): -1.1052258607991248
Total shareholder yield (%): -1.1052258607991248 (Minimal or Negative)
Momentum (%): 1m 20, 3m 16.546762589928075, 6m -4.705882352941168, 12m -41.72661870503596, composite -13.199322894625462 (Strong Downtrend)
Lynch category: Turnaround (confidence: High)
Screener: long score 2, short score 11, recommendation: Strong Short (Melting Ice Cube)
Revenue growth 1y (%): -100
Revenue deceleration: no
Accrual ratio: -0.06890268012171431
FCF conversion rate: 0.6293693360458664
Beneish M-score: -2.6628523730382256 (Likely Safe)
ROE (%): -25.06257532214703
Asset turnover: 0
Equity multiplier (leverage): 1.348127375544637
ROE archetype: Low Return
Treasury beta 1y: 0.011292626222302699 (R-squared: 0.003997791142240818)
Insider 90-day net shares: 0 (net value USD: 0.00)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B 17.23826714801444, ROIC , revenue growth 1y 29.693140794223826, 6m momentum 31.5884476534296
Sector percentiles: P/E , 6m momentum 34.777936962750715
Industry median P/E: 6.198133227515053; industry median ROIC: -89.41034195162634
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.09963362121280306
Base cash flow: -46891000
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for JUNS (Healthcare — Biotechnology, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 0.12
Market cap: 5835117 (USD: 5835117)
Debt to equity: -1.7363009380062275
Current ratio: 0.51
Interest coverage ratio: -16.545295168740097
Buffett classification: The Gruesome
Rule of 40 score: -10378.417802541313
Altman Z-score: -15.147849278927486 (Distress Zone)
Piotroski F-score: 3 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 8.335668333642667
Total shareholder yield (%): 8.335668333642667 (Moderate Return)
Momentum (%): 1m -52, 3m -69.23076923076923, 6m -86.51685393258427, 12m -92.81437125748502, composite -80.25918776103799 (Strong Downtrend)
Lynch category: Turnaround (confidence: High)
Screener: long score 1, short score 11, recommendation: Strong Short (Melting Ice Cube)
Revenue deceleration: no
Accrual ratio: -0.13242585056010892
FCF conversion rate: 0.6945340302760774
Beneish M-score: -4.015210956501765 (Likely Safe)
Net margin (%): -11054.889556079777
Asset turnover: 0.003921529876015152
ROE archetype: Standard Business
Treasury beta 1y: 0.007995739725873982 (R-squared: 0.0009423905074128999)
Insider 90-day net shares: 0 (net value USD: 0.00)
Incremental ROIC 3y (%): -86.37911394578602 (pretax: -109.34065056428612)
Capital allocation category: Value Destroyer
Industry percentiles: P/E , P/B , ROIC , revenue growth 1y , 6m momentum 77.88808664259928
Sector percentiles: P/E , 6m momentum 79.4054441260745
Industry median P/E: 6.198133227515053; industry median ROIC: -89.41034195162634
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.09291263608044009
Base cash flow: -8644897
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for KLRA (Healthcare — Biotechnology, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 17.69
Market cap: 2292015616 (USD: 2292015616)
Debt to equity: 0.0187
Current ratio: 9.67
Buffett classification: The Gruesome
Rule of 40 score: 0
Altman Z-score: 0.7644729980557963 (Distress Zone)
Piotroski F-score: 2 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Total shareholder yield (%): 0 (Minimal or Negative)
Momentum (%): 1m -17.220402433317734, 3m -21.27280818869603, 6m , 12m , composite -21.27280818869603 ()
Lynch category: Turnaround (confidence: High)
Screener: long score 2, short score 9, recommendation: Short
Revenue deceleration: no
Accrual ratio: -0.016894595650141814
FCF conversion rate: 0.8661636974576808
Beneish M-score: 11.088242624653338 (Strong Manipulation Signal)
Asset turnover: 0
ROE archetype: Standard Business
Treasury beta 1y: 0.001631485431075358 (R-squared: 0.0003978353746021197)
Insider 90-day net shares: 20421876 (net value USD: 528101901.00)
Capital allocation category: Standard Allocator
Industry median P/E: 6.198133227515053; industry median ROIC: -89.41034195162634
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.052851
Base cash flow: -150733000
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for KMTS (Healthcare — Medical Instruments & Supplies, United States)
Report date: 2026-04-30 (annual)
Stock price: 21.06
Market cap: 1234168576 (USD: 1234168576)
P/B ratio: 4.6763193810319725
Debt to equity: 0.1802
Current ratio: 4.41
Interest coverage ratio: -17.855950172276703
Return on net tangible assets (%): -60.97366535981945
Buffett classification: The Gruesome
Analyst consensus upside (%): 44.7876447876448
Rule of 40 score: -99.45820775816154
Altman Z-score: 5.241987430179404 (Safe Zone)
Piotroski F-score: 4 (Weak)
Dividend yield (%): 0.024145810045320744
Buyback yield (%): 0
Debt paydown yield (%): -0.01977039480220893
Total shareholder yield (%): 0.0043754152431118125 (Low Return)
Momentum (%): 1m -4.619565217391303, 3m -6.191536748329624, 6m -14.390243902439034, 12m 24.101355332940482, composite 3.1767272118730276 (Strong Uptrend)
Lynch category: Speculative (confidence: Low)
Screener: long score 4, short score 8, recommendation: Short
Revenue growth 1y (%): 59.033687202206806
Revenue CAGR 3y (%): 131.87729875776856
Revenue deceleration: yes
Revenue growth consistency score: 106.2336449901693
Accrual ratio: -0.04429471315741605
FCF conversion rate: 0.8899112542929216
Beneish M-score: 4.058702925898579 (Strong Manipulation Signal)
ROE (%): -56.59952178624877
Net margin (%): -138.35544435800938
Asset turnover: 0.29081226335926286
Equity multiplier (leverage): 1.4067074639189445
ROE archetype: Low Return
Treasury beta 1y: 0.00960903332337114 (R-squared: 0.004071955498649569)
Insider 90-day net shares: -45000 (net value USD: -963080.00)
ROIC (%): -96.75534245330182 (pretax: -122.47511702949598)
Incremental ROIC 3y (%): -21.111335225735356 (pretax: -26.723209146500448)
Capital allocation category: Value Destroyer
Industry percentiles: P/E , P/B 58.282208588957054, ROIC 77.30061349693251, revenue growth 1y 4.9079754601226995, 6m momentum 57.05521472392638
Sector percentiles: P/E , 6m momentum 44.126074498567334
Industry median P/E: 15.690276110444179; industry median ROIC: 5.717819487534456
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.10283159622080065
Base cash flow: -158323000
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for KRYS (Healthcare — Biotechnology, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 335.19
Market cap: 9881319424 (USD: 9881319424)
P/E ratio: 34.53475935828877
P/B ratio: 5.964625672260911
Debt to equity: 0.0070999999999999995
Current ratio: 9.46
Return on net tangible assets (%): 3.9562037049365997
Buffett classification: The Great
Analyst consensus upside (%): 45.84623722514711
Rule of 40 score: 59.88140901872611
Altman Z-score: 50.38254931471951 (Safe Zone)
Piotroski F-score: 8 (Strong)
Magic formula: return on capital % 5.0057059957708505, earnings yield % 0.5921345923346703, rank 1623
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 0.002297264062212751
Total shareholder yield (%): 0.002297264062212751 (Low Return)
Momentum (%): 1m -3.5785173891781485, 3m 22.996477322765312, 6m 19.06013568713815, 12m 123.46, composite 57.93664878107893 (Strong Uptrend)
Lynch category: Slow Grower (confidence: Medium)
Screener: long score 8, short score 2, recommendation: Long
Revenue growth 1y (%): 31.949468718460473
Net income growth 1y (%): 56.52757954831669
Revenue deceleration: no
Accrual ratio: -0.01267192551819804
FCF conversion rate: 1.309339912751198
Beneish M-score: -2.4055254149885155 (Likely Safe)
ROE (%): 4.48121191096063
Net margin (%): 48.06930395249104
Asset turnover: 0.08521946812628421
Equity multiplier (leverage): 1.0939282270602482
ROE archetype: Low Return
P/E z-score: 3.737033081728612
FCF z-score: 2.847281087804953
Treasury beta 1y: 0.0016228378280701322 (R-squared: 0.0003129311597941717)
Insider 90-day net shares: -51642 (net value USD: -15946982.00)
ROIC (%): 31.767765788765125 (pretax: 40.21236175793053)
Incremental ROIC 3y (%): 89.26716175260422 (pretax: 112.9964072817775)
Capital allocation category: High-Efficiency Compounder
Industry percentiles: P/E 11.64259927797834, P/B 50.18050541516246, ROIC 2.707581227436823, revenue growth 1y 11.101083032490974, 6m momentum 15.884476534296029
Sector percentiles: P/E 29.011461318051573, 6m momentum 14.899713467048711
Industry median P/E: 6.198133227515053; industry median ROIC: -89.41034195162634
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.07437234596372758
Base cash flow: 199431000
DCF price per share: base 405.2898748791093, conservative 231.10828516093878, aggressive 732.9418491037703
Financial scorecard for KSI.TO (Healthcare — Health Information Services, Ireland)
Report date: 2026-03-31 (quarterly)
Stock price: 4.609929078014185
Market cap: 627717248 (USD: 721514078.1609195)
P/B ratio: 3.3434878182144456
Debt to equity: 0.4242
Current ratio: 1.41
Interest coverage ratio: -3.123540089919057
Return on net tangible assets (%): -0.2124607542831394
Buffett classification: The Gruesome
Analyst consensus upside (%): 152.90830945558733
Rule of 40 score: 8.12013884599182
Altman Z-score: 4.415052646895935 (Safe Zone)
Piotroski F-score: 5 (Neutral)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 0.3805709293981172
Total shareholder yield (%): 0.3805709293981172 (Low Return)
Momentum (%): 1m 1.3328063588257164, 3m 42.88694201084691, 6m 31.169116034218035, 12m 9.991290282443698, composite 27.533552994677365 (Flat)
Lynch category: Speculative (confidence: Low)
Screener: long score 6, short score 9, recommendation: Neutral
Revenue growth 1y (%): 29.08367896410273
Net income growth 1y (%): -294.434926643661
Revenue deceleration: no
Accrual ratio: -0.04445462663388372
FCF conversion rate: -0.4818921871780582
Beneish M-score: -2.2531262709541546 (Likely Safe)
ROE (%): -6.0871101055515044
Net margin (%): -21.918351151629395
Asset turnover: 0.13686502410760806
Equity multiplier (leverage): 2.029134331101077
ROE archetype: Low Return
Treasury beta 1y: 0.0002153711954288365 (R-squared: 4.1681516775921e-06)
Insider 90-day net shares: 0 (net value USD: 0.00)
ROIC (%): -14.907321881419428 (pretax: -18.870027697999276)
Incremental ROIC 3y (%): 1.1917611243486543 (pretax: 1.5085583852514612)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B 40, ROIC 41.578947368421055, revenue growth 1y 11.578947368421053, 6m momentum 7.368421052631578
Sector percentiles: P/E , 6m momentum 10.315186246418339
Industry median P/E: 8.33027298322928; industry median ROIC: 0.6291287571896624
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.11848179598885522
Base cash flow: 13368410.588235296
DCF price per share: base 3.8689094782109086, conservative 2.40462702986897, aggressive 6.390894061667522
Financial scorecard for LAW (Technology — Software - Application, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 3.52
Market cap: 225753120 (USD: 225753120)
P/B ratio: 1.9765983115363823
Debt to equity: 0.051
Current ratio: 4.19
Return on net tangible assets (%): -7.920229370249729
Buffett classification: The Gruesome
Analyst consensus upside (%): 74.60732984293195
Rule of 40 score: -40.81877997739568
Altman Z-score: 1.3499435472060988 (Distress Zone)
Piotroski F-score: 4 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0.05847095269380995
Debt paydown yield (%): 0.2879251458407308
Total shareholder yield (%): 0.3463960985345408 (Low Return)
Momentum (%): 1m -0.56497175141243, 3m -14.769975786924938, 6m -46.25954198473282, 12m -14.146341463414627, composite -24.896018119007866 (Moderate Downtrend)
Lynch category: Turnaround (confidence: High)
Screener: long score 2, short score 15, recommendation: Strong Short (Melting Ice Cube)
Revenue growth 1y (%): 14.266226502605516
Revenue deceleration: no
Accrual ratio: 0.016463746722577534
FCF conversion rate: 1.2875857766687462
Beneish M-score: -2.3519972081988114 (Likely Safe)
ROE (%): -7.63169796948273
Net margin (%): -22.964519363927224
Asset turnover: 0.2492894577856082
Equity multiplier (leverage): 1.3330913217009053
ROE archetype: Low Return
Treasury beta 1y: 0.018210116355338604 (R-squared: 0.011034263042703907)
Insider 90-day net shares: -22616 (net value USD: -78404.00)
ROIC (%): -185.62550656706216 (pretax: -234.96899565450903)
Capital allocation category: Capital-Light Grower
Industry percentiles: P/E , P/B 28.84097035040431, ROIC 75.87601078167116, revenue growth 1y 25.202156334231805, 6m momentum 81.26684636118598
Sector percentiles: P/E , 6m momentum 75.87587587587588
Industry median P/E: 2.1394954536591486; industry median ROIC: 6.21806735836372
Sector median P/E: 1.5433673469387754; sector median ROIC: 6.677876317240262
WACC: 0.15
Base cash flow: -43759000
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for LBNK.V (Basic Materials — Other Industrial Metals & Mining, Canada)
Report date: 2026-03-31 (quarterly)
Stock price: 0.3333333333333333
Market cap: 31616716 (USD: 22745838.848920863)
P/B ratio: 5.688264351079356
Debt to equity: 0
Current ratio: 2.5403342644966513
Return on net tangible assets (%): -33.86504612365145
Buffett classification: The Gruesome
Rule of 40 score: 0
Altman Z-score: 7.842928834325934 (Safe Zone)
Piotroski F-score: 2 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Total shareholder yield (%): 0 (Minimal or Negative)
Momentum (%): 1m 7.575757575757559, 3m -31.840796019900502, 6m -24.590163934426236, 12m 37.37373737373736, composite -9.577143145964934 (Strong Uptrend)
Lynch category: Cyclical (confidence: High)
Screener: long score 4, short score 9, recommendation: Short
Revenue deceleration: no
Accrual ratio: -0.08517662995791889
FCF conversion rate: 0.6809359695265736
Beneish M-score: -2.680731720321046 (Likely Safe)
ROE (%): -30.08458855685785
Asset turnover: 0
Equity multiplier (leverage): 1.1269417544258424
ROE archetype: Low Return
Treasury beta 1y: 0.004773060625401514 (R-squared: 0.00038121402141237475)
Insider 90-day net shares: 0 (net value USD: 0.00)
ROIC (%): -89.7992315380287 (pretax: -113.66991333927683)
Incremental ROIC 3y (%): -218.05342130013844 (pretax: -276.0169889875171)
Capital allocation category: Value Destroyer
Industry percentiles: P/E , P/B 45.71190674437968, ROIC 49.2089925062448, revenue growth 1y , 6m momentum 38.46794338051623
Sector percentiles: P/E , 6m momentum 49.50027762354247
Industry median P/E: 6.295008083084309; industry median ROIC: -14.271466134226909
Sector median P/E: 1.5790983881237224; sector median ROIC: -1.992018401665734
WACC: 0.1019
Base cash flow: -6971632.3741007205
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for LIB.V (Basic Materials — Other Industrial Metals & Mining, Canada)
Report date: 2026-03-31 (quarterly)
Stock price: 0.5815602836879432
Market cap: 176836928 (USD: 127220811.51079138)
P/B ratio: 53.99240055696573
Debt to equity: 0.7681
Current ratio: 1.87
Interest coverage ratio: -61.757373178144924
Return on net tangible assets (%): -490.74971821138024
Buffett classification: The Gruesome
Analyst consensus upside (%): 207.02197802197796
Rule of 40 score: 0
Altman Z-score: 3.0856798069113296 (Safe Zone)
Piotroski F-score: 3 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): -0.00918446900791891
Total shareholder yield (%): -0.00918446900791891 (Minimal or Negative)
Momentum (%): 1m -24.23710065716704, 3m -11.473601260835308, 6m -46.13736969870057, 12m 192.93406882059367, composite 76.34494325692398 (Strong Uptrend)
Lynch category: Cyclical (confidence: High)
Screener: long score 3, short score 9, recommendation: Short
Revenue deceleration: no
Accrual ratio: 0.5912251355780134
FCF conversion rate: 7.947946906798133
Beneish M-score: -3.0465998347177705 (Likely Safe)
ROE (%): -110.49050839303307
Asset turnover: 0
Equity multiplier (leverage): 12.984599940416945
ROE archetype: Low Return
Treasury beta 1y: -0.0024980288854349014 (R-squared: 7.430565295030238e-05)
Insider 90-day net shares: -223600 (net value USD: -174909.00)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B 59.36719400499584, ROIC , revenue growth 1y , 6m momentum 59.20066611157368
Sector percentiles: P/E , 6m momentum 68.26762909494725
Industry median P/E: 6.295008083084309; industry median ROIC: -14.271466134226909
Sector median P/E: 1.5790983881237224; sector median ROIC: -1.992018401665734
WACC: 0.10429479256884878
Base cash flow: -12290571.532846713
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for LIF (Technology — Software - Application, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 48.86
Market cap: 3959208448 (USD: 3959208448)
P/E ratio: 23.325714285714287
P/B ratio: 5.5347181811823365
Debt to equity: 0.5207
Current ratio: 5.37
Return on net tangible assets (%): 2.421542999839362
Buffett classification: The Gruesome
Analyst consensus upside (%): 57.300342969132764
Rule of 40 score: -2.402216211393959
Altman Z-score: 5.841845383736779 (Safe Zone)
Piotroski F-score: 6 (Neutral)
Magic formula: return on capital % 3.7020059765774342, earnings yield % 0.4982428249588901, rank 5259
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): -0.013740120206977291
Total shareholder yield (%): -0.013740120206977291 (Minimal or Negative)
Momentum (%): 1m -1.1331444759206843, 3m 6.727828746177367, 6m -28.2525697503671, 12m -35.14733209450491, composite -18.642925348445512 (Strong Downtrend)
Lynch category: Slow Grower (confidence: Medium)
Screener: long score 4, short score 11, recommendation: Short
Revenue growth 1y (%): 38.11761754033816
Net income growth 1y (%): -36.52352672453175
Revenue deceleration: no
Accrual ratio: -0.012834393535416547
FCF conversion rate: 5.619647355163728
Beneish M-score: -2.435492304314877 (Likely Safe)
ROE (%): 0.4850708493190855
Net margin (%): 1.9416865213837051
Asset turnover: 0.14308279373496047
Equity multiplier (leverage): 1.7459775251088312
ROE archetype: Low Return
P/E z-score: 1.4697642945206513
FCF z-score: 3.316905450380408
Treasury beta 1y: 0.012574962215649296 (R-squared: 0.006981538553776491)
Insider 90-day net shares: -87211 (net value USD: -4154984.00)
ROIC (%): 4.115597559201443 (pretax: 5.20961716354613)
Incremental ROIC 3y (%): 47.94708473614627 (pretax: 60.69251232423579)
Capital allocation category: Turnaround Compounder
Industry percentiles: P/E 43.126684636118604, P/B 56.334231805929925, ROIC 42.722371967654986, revenue growth 1y 8.89487870619946, 6m momentum 62.8032345013477
Sector percentiles: P/E 41.77510844177511, 6m momentum 63.46346346346346
Industry median P/E: 2.1394954536591486; industry median ROIC: 6.21806735836372
Sector median P/E: 1.5433673469387754; sector median ROIC: 6.677876317240262
WACC: 0.10484493326279799
Base cash flow: 162717000
DCF price per share: base 65.94368533007457, conservative 39.25638352948208, aggressive 112.81223056659832
Financial scorecard for LNSR (Healthcare — Medical Devices, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 5.6
Market cap: 68776856 (USD: 68776856)
P/E ratio: 2.489989548593394
P/B ratio: 6.783894602409639
Debt to equity: 0.1047
Current ratio: 2.38
Return on net tangible assets (%): 642.8448867536033
Buffett classification: The Great
Analyst consensus upside (%): 42.61744966442953
Rule of 40 score: -53.151117394114884
Altman Z-score: -1.4813790116578707 (Distress Zone)
Piotroski F-score: 5 (Neutral)
Magic formula: return on capital % 5.562180156009341, earnings yield % 3.1692674759834922, rank 536
Dividend yield (%): 0
Buyback yield (%): 0
Debt paydown yield (%): 0.23409037482027387
Total shareholder yield (%): 0.23409037482027387 (Low Return)
Momentum (%): 1m -7.590759075907591, 3m 10.019646365422393, 6m -55.23581135091926, 12m -56.68986852281515, composite -32.78280518851442 (Strong Downtrend)
Lynch category: Slow Grower (confidence: Low)
Screener: long score 4, short score 4, recommendation: Neutral
Revenue growth 1y (%): -5.162793982625891
Revenue deceleration: no
Accrual ratio: 0.5899326567528496
FCF conversion rate: -0.11755477265220741
Beneish M-score: -2.022464310796022 (Likely Safe)
Net margin (%): 270.5689603812928
Asset turnover: 0.19509927135623634
ROE archetype: Standard Business
Treasury beta 1y: 0.01664398100808667 (R-squared: 0.01675188872128455)
Insider 90-day net shares: 0 (net value USD: 0.00)
Capital allocation category: Standard Allocator
Industry percentiles: P/E 10.385756676557865, P/B 53.41246290801187, ROIC , revenue growth 1y 48.6646884272997, 6m momentum 69.13946587537092
Sector percentiles: P/E 15.759312320916905, 6m momentum 72.34957020057307
Industry median P/E: 21.626420273203117; industry median ROIC: -5.9391058628332924
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.09396279155971847
Base cash flow: -29861000
DCF price per share: base 0, conservative 0, aggressive 0
Financial scorecard for MAIR (Industrials — Building Products & Equipment, United States)
Report date: 2026-03-31 (quarterly)
Stock price: 34.73
Market cap: 17410748416 (USD: 17410748416)
Debt to equity: 5.6114
Current ratio: 1.77
Interest coverage ratio: 1.6945975744211688
Return on net tangible assets (%): -1.3779830638953041
Buffett classification: The Great
Rule of 40 score: 39.172539440667045
Altman Z-score: 1.692925803220167 (Distress Zone)
Piotroski F-score: 5 (Neutral)
Magic formula: return on capital % 16.596479861785983, earnings yield % 0.6406318916486332, rank 877
Dividend yield (%): 0
Buyback yield (%): 0
Total shareholder yield (%): 0 (Minimal or Negative)
Momentum (%): 1m -11.852791878172592, 3m 2.660360626662721, 6m , 12m , composite 2.660360626662721 ()
Lynch category: Cyclical (confidence: High)
Screener: long score 3, short score 6, recommendation: Neutral
Revenue deceleration: no
Accrual ratio: -0.0008063351465845088
FCF conversion rate: 1.155813953488372
Beneish M-score: -1.3743699659396302 (Strong Manipulation Signal)
ROE (%): 4.166666666666666
Net margin (%): 4.655191079354768
Asset turnover: 0.11116593655225533
Equity multiplier (leverage): 8.0515503875969
ROE archetype: Low Return
P/E z-score: 0.6022201272870561
FCF z-score: 0.6022201272870564
Treasury beta 1y: 0.010274796295422354 (R-squared: 0.025200812014004294)
Insider 90-day net shares: 0 (net value USD: 0.00)
ROIC (%): 5.902137904817074 (pretax: 9.080212161257037)
Capital allocation category: Standard Allocator
Industry percentiles: P/E , P/B , ROIC 48.18652849740933, revenue growth 1y , 6m momentum 
Industry median P/E: 0.3265277733522184; industry median ROIC: 6.830432455396816
Sector median P/E: 0.48479532163742683; sector median ROIC: 7.0952301251284755
WACC: 0.05
Base cash flow: 210300000
DCF price per share: base 110.58173370688998, conservative 36.73681274263505, aggressive 273.5338768663187
Financial scorecard for MBX.TO (Healthcare — Biotechnology, Canada)
Report date: 2026-03-31 (quarterly)
Stock price: 0.2127659574468085
Market cap: 41250348 (USD: 29676509.35251799)
P/B ratio: 1.2579521149288804
Debt to equity: 0.2703
Current ratio: 5.35
Interest coverage ratio: -4.923710302756087
Return on net tangible assets (%): -5.493199626466323
Buffett classification: The Gruesome
Analyst consensus upside (%): 141.7391304347826
Rule of 40 score: -41.26565123805232
Altman Z-score: 1.4929718388200695 (Distress Zone)
Piotroski F-score: 3 (Weak)
Dividend yield (%): 0
Buyback yield (%): 0.45479616317418703
Debt paydown yield (%): 0.4138257501337792
Total shareholder yield (%): 0.8686219133079662 (Low Return)
Momentum (%): 1m 4.181951577402786, 3m 16.595744680851066, 6m 33.4622823984526, 12m -0.2201027146001291, composite 15.277558322209211 (Moderate Downtrend)
Lynch category: Turnaround (confidence: High)
Screener: long score 2, short score 11, recommendation: Strong Short (Melting Ice Cube)
Revenue growth 1y (%): -34.74184072652696
Net income growth 1y (%): -7221.074360024176
Revenue deceleration: no
Accrual ratio: -0.024829201201243534
FCF conversion rate: 0.3708242387463663
Beneish M-score: -2.9337006845083313 (Likely Safe)
ROE (%): -5.48696215352092
Net margin (%): -42.34640768236923
Asset turnover: 0.09319104682237797
Equity multiplier (leverage): 1.3904046134752417
ROE archetype: Low Return
Treasury beta 1y: 0.0019429070331736745 (R-squared: 0.00022771779581522454)
Insider 90-day net shares: 258500 (net value USD: 50441.00)
ROIC (%): -5.5465421421002645 (pretax: -7.020939420380082)
Incremental ROIC 3y (%): -76.85765663542495 (pretax: -85.8073345305581)
Capital allocation category: Value Destroyer
Industry percentiles: P/E , P/B 14.350180505415164, ROIC 10.920577617328519, revenue growth 1y 23.014440433212997, 6m momentum 11.732851985559567
Sector percentiles: P/E , 6m momentum 9.670487106017193
Industry median P/E: 6.198133227515053; industry median ROIC: -89.41034195162634
Sector median P/E: 4.824561403508772; sector median ROIC: 0.94429175936832
WACC: 0.08203077645670108
Base cash flow: -909174.8201438849
DCF price per share: base 0, conservative 0, aggressive 0